Business Wire

Thermo Fisher Scientific Launches CE-IVD Marked Next-Generation Sequencing Instrument for Use in Clinical Labs

Share

Thermo Fisher Scientific today launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated, next-generation sequencing (NGS) platform that delivers results in as little as a single day. Designed for use in clinical laboratories, the fully validated system enables users to perform both diagnostic testing and clinical research on a single instrument.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220329005106/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer enables rapid NGS for diagnostic applications and clinical research. (Photo: Business Wire)

“Next-generation sequencing has become an essential tool to bring the promise of precision medicine therapies to patients. With the automated, easy-to-use Genexus Dx Integrated Sequencer, any hospital – including regional and community hospitals – can bring NGS in-house, giving clinicians access to timely, comprehensive genomic profiling results,” said Garret Hampton, president, clinical next-generation sequencing and oncology at Thermo Fisher Scientific. “With faster answers, the results can aid clinicians in their patient management decision making which may include therapeutic options.”

In support of increasing physicians’ access to rapid NGS results, Thermo Fisher is also developing a complete sample-to-report diagnostic workflow and a portfolio of clinically validated assays, including those for comprehensive genomic profiling and hemato-oncology, on the Genexus System.

Thermo Fisher introduced the Ion Torrent Genexus System for research use only in 2019 as the first fully integrated NGS platform that delivers results in as little as 24 hours. The platform’s automated workflow minimizes user intervention and the potential for human error, making NGS accessible for all labs.

For more information on the Ion Torrent Genexus Dx Integrated Sequencer, please visit thermofisher.com/genexusDx.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mauricio Minotta
Phone: 760-805-5266
Email: mauricio.minotta@thermofisher.com

Jessika Parry
Phone: 419-266-4016
Email: jparry@greenough.biz

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The 2022 .eu Web Awards Will Kick off Today!17.5.2022 14:50:00 EEST | Press release

The 2022 .eu Web Awards nomination and voting period kicks off today and will run until 17 August 2022. Any eligible person under the Web Awards rules can nominate their own or their favourite .eu, .ею, or .ευ website. Once entered, nominees and their fans should campaign to get as many votes as possible via webawards.eurid.eu. Voting is as simple as a click of a button! The 18 finalists (three per category) will be revealed on 1 September 2022 and will be invited to the .eu Web Awards ceremony held on 17 November 2022 in Mechelen, Belgium, where the winners will be announced. The winners will receive a prestigious award package, including: An online marketing budget of € 5.000 (to be coordinated by a EURid appointed marketing agency) Website improvement package – experts’ analyses and reports on accessibility and design improvements A digital winner’s icon Visit webawards.eurid.eu to learn more about the categories and submit your nomination and cast your vote for the best .eu, .ею, a

University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder (PTSD)17.5.2022 14:05:00 EEST | Press release

The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc announce a collaboration in a new clinical trial investigating treatment for adults with Post-Traumatic Stress Disorder (PTSD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005065/en/ (Photo: Business Wire) The trial is being led by principal investigator Mathew Rizzo, M.D., the Reynolds Professor and chair of the UNMC Department of Neurological Sciences and Chief Physician for neurological services at Nebraska Medicine. The study will evaluate the effectiveness of Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the U.S. Food and Drug Administration (FDA). (Clinical Trials.gov Identifier NCT05269459) “This is our second clinical trial targeting PTSD. We are excited that UNMC’s research team has partnered with

Trilio Announces Technical Preview of ‘Continuous Restore,’ Delivering Cloud-Native Application Portability and Recoverability in Seconds Across Disparate Infrastructure17.5.2022 14:05:00 EEST | Press release

KUBECON + CLOUDNATIVECON EUROPE— Trilio, a leading provider of cloud-native data protection, today announced a technical preview of a new “Continuous Restore” capability that is being showcased to the cloud-native community at the KubeCon + CloudNativeCon Europe conference. Continuous Restore offers faster levels of replication, restoration and migration of data and metadata from any storage or cloud platform to another, dramatically improving recovery times for cloud-native applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005514/en/ New capability unlocks data gravity and frees data-driven organizations to quickly replicate production-grade Cloud-Native applications to any cloud in seconds. (Graphic: Business Wire) Entirely storage-, cloud- and distribution-agnostic, Trilio’s “Continuous Restore” capability will enable users to continuously stage data at multiple and heterogeneous clouds. This means that a

Forge Biologics Forms Independent Scientific and Manufacturing Advisory Board with Panel of Gene Therapy Leaders17.5.2022 14:00:00 EEST | Press release

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today the formation of an independent board of preeminent experts, a Scientific and Manufacturing Advisory Board (SMAB), to advise the Company on its gene therapy manufacturing offerings and therapeutics pipeline development. The board will serve the traditional functions of a scientific advisory board, with a distinct and strategic emphasis on manufacturing advancements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005561/en/ Credit: Forge Biologics “We are thrilled and privileged to have gathered such a renowned group of experts in gene therapy development and manufacturing to work with us to us deliver quality products to our clients, especially as we accelerate AAV production with our new 5,000L bioreactor,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics. “The board’s guidance w

Philip Morris International Releases 2021 Integrated Report, Introducing New Sustainability Strategy and Sustainability Index17.5.2022 13:00:00 EEST | Press release

Today, Philip Morris International Inc. (PMI) (NYSE: PM) released its third annual Integrated Report, which includes an updated Statement of Purpose, a new environmental, social, and governance (ESG) framework, as well as detailed information about PMI’s strategic vision, performance, governance, and value creation model. The content was informed by a formal sustainability materiality assessment conducted in 2021. “Sustainability and business performance are fully interrelated and mutually reinforcing. Our actions—grounded in data, science, and facts—speak louder than words. PMI is committed to serving as an agent of change and advocate of positive values. We understand that our business must become a provider of effective alternatives to continued smoking for adult smokers who don’t quit. To achieve this, we are positioning ourselves at the forefront of consumer-centricity, technology, science, and innovation. With an eye to the long term, we are also expanding our business into areas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom